There is a recent retrospective review by Ho et al which looked at the toxicity profiles associated with "novel" oral lymphoma agents of ibrutinib, venetoclax, and lenalidomide concurrent with radiation treatment for lymphoma, as compared to sequential therapy of novel agent followed by RT (separate...